Centessa Pharmaceuticals Plc

CNTA

Pharmaceutical Preparations

Mkt Cap

$1.089B

PE

-7.21

Debt

$75.7M

Cash

$128M

EV

$1.037B

FCF

-$160.5M

Market Cap

$1.089B

P/E Ratio

-7.21

Debt

$75.7M

Cash

$128M

EV

$1.037B

FCF

-$160.5M

Charts data: {"Earnings":[{"time":"2019-12-30","value":-5061000},{"time":"2020-12-30","value":-10663000},{"time":"2021-12-30","value":-381071000},{"time":"2022-12-30","value":-216207000},{"time":"2023-12-30","value":-151085000}],"Sales":[{"time":"2022-12-30","value":0},{"time":"2023-12-30","value":6853000}],"Net Margins":[{"time":"2023-12-30","value":-22.046548956661315}],"Assets":[{"time":"2020-12-30","value":11717000},{"time":"2021-12-30","value":629635000},{"time":"2022-12-30","value":444307000},{"time":"2023-12-30","value":360246000}],"Stockholders Equity":[{"time":"2019-12-30","value":-11857000},{"time":"2020-12-30","value":-22423000},{"time":"2021-12-30","value":491554000},{"time":"2022-12-30","value":336169000},{"time":"2023-12-30","value":236244000}],"ROE":[{"time":"2019-12-30","value":0.4268364679092519},{"time":"2020-12-30","value":0.4755385095660706},{"time":"2021-12-30","value":-0.7752373086171611},{"time":"2022-12-30","value":-0.6431497252869837},{"time":"2023-12-30","value":-0.6395294695315014}],"ROA":[{"time":"2020-12-30","value":-0.8910130579499872},{"time":"2021-12-30","value":-0.5941283441994171},{"time":"2022-12-30","value":-0.47773949093757245},{"time":"2023-12-30","value":-0.47546121261582364}]}

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

Sector

10-Q
9/30/23
10-Q
6/30/23
10-Q
3/31/23
10-K
12/31/22
10-Q
9/30/22
10-Q
6/30/22
10-Q
3/31/22
10-K
12/31/21
10-Q
9/30/21
10-Q
6/30/21

Chart P/E ratio

In the chart Earnings are multiplied by this value.

Earnings Growth -

Earnings Stability -

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

The Net Margin is too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Data are missing

Years	12-2019	12-2020	12-2021	12-2022	12-2023	TTM
Net Margin	-	-	-	-	-2.2K%	-2.2K%
ROA	-	-89%	-59%	-48%	-48%	-48%
ROE	43%	48%	-78%	-64%	-64%	-64%

What is the average Net Margin?

The average Net Margin over the past 5 years is -2.2K%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is -.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is -47.55%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is -.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is -63.95%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is -.

Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Under the assumption that FCF does not diminish and debt does not increase, the current years to repay the debt are acceptable.

Data are missing

Years	12-2019	12-2020	12-2021	12-2022	12-2023	TTM
Debt FCF	-	-0.53	-0.56	-0.35	-0.47	-0.47
Debt Equity	-	-0.25	0.15	0.21	0.32	0.32
MIN
Graham Stability	-	-	-	-	-	-

What is the Debt/FCF?

The Debt/FCF trailing twelve month is -0.47.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is -.

What is the Graham’s Stability?

Graham’s Stability measure stands at -.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Data are missing

Years	12-2020	12-2022	Trend
Revenue	-	-	-
Net Income	-	-	-
Stockholders Equity	-	-30%	1.9%
FCF	-	-	-

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is -.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is -.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is -.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is -.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is -.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is +1.89%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is -.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is -.